Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Areata Alopecia Clear all
Active, not recruiting No phase listed Observational

Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

NCT07226531
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 11, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Results available

A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

NCT03354637
View directory record Official record
Conditions
Alopecia Areata
Interventions
ATI-50002 high dose, ATI-50002 low dose, Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
23
States / cities
Encinitas, California • Laguna Hills, California • Redwood City, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

NCT01023841
View directory record Official record
Conditions
Eyelash Hypotrichosis, Alopecia Areata
Interventions
bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jun 11, 2026, 6:50 AM EDT
Withdrawn Phase 2 Interventional

Topical Crisaborole in Patients with Alopecia Areata

NCT04299503
View directory record Official record
Conditions
Alopecia Areata
Interventions
Crisaborole Topical Ointment, Placebo Topical Ointment
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

PF-06651600 for the Treatment of Alopecia Areata

NCT03732807
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jun 11, 2026, 6:50 AM EDT
Not listed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

NCT05205070
View directory record Official record
Conditions
Alopecia Areata
Interventions
Rosnilimab, Placebo
Biological
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Encinitas, California • Northridge, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT04784533
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 11, 2026, 6:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

NCT06826196
View directory record Official record
Conditions
Alopecia Areata (AA)
Interventions
ALD-102 Solution, Placebo or Control
Drug · Other
Lead sponsor
Aldena Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Thousand Oaks, California • West Lafayette, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling

NCT04338295
View directory record Official record
Conditions
Alopecia Areata
Interventions
Tattoo machine (SOL Nova Device)
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata

NCT02018042
View directory record Official record
Conditions
Alopecia Areata
Interventions
Abatacept
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

NCT04556734
View directory record Official record
Conditions
Alopecia Areata
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
39
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Encinitas, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Aldara for the Treatment of Extensive Alopecia Areata

NCT00177021
View directory record Official record
Conditions
Alopecia Areata
Interventions
Aldara Cream 5%
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2006 · Synced Jun 11, 2026, 6:50 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata

NCT01385839
View directory record Official record
Conditions
Alopecia Areata, Alopecia, Balding
Interventions
Hair transplantation, Hypodermic needle irritation
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Jun 11, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

Regeneron AA Multicenter (Dupilumab)

NCT05551793
View directory record Official record
Conditions
Alopecia Areata
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Emma Guttman
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Irvine, California • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jun 11, 2026, 6:50 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

NCT06340360
View directory record Official record
Conditions
Alopecia Areata
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Northridge, California • Atlanta, Georgia • Gurnee, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

NCT01950780
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ruxolitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jun 11, 2026, 6:50 AM EDT
Recruiting No phase listed Observational

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

NCT06562270
View directory record Official record
Conditions
Alopecia Areata
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
12 Years to 17 Years
Enrollment
1,500 participants
Timeline
2024 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 11, 2026, 6:50 AM EDT
Not listed Early Phase 1 Interventional

Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata

NCT05414266
View directory record Official record
Conditions
Alopecia Areata
Interventions
Placebo, SADBE 5%
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
12 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Jun 11, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

NCT07242638
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata
Interventions
Abrocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 11, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

A Study of LAD603 in Adults With Alopecia Areata

NCT07311564
View directory record Official record
Conditions
Alopecia Areata
Interventions
LAD603, Placebo
Drug · Other
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling

NCT04341363
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Tattoo machine
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Vytorin in the Treatment of Alopecia Areata

NCT01520077
View directory record Official record
Conditions
Alopecia Areata
Interventions
vytorin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Jun 11, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Response of Topical Capsaicin in Alopecia Areata

NCT00176969
View directory record Official record
Conditions
Alopecia Areata
Interventions
Capsaicin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jun 11, 2026, 6:50 AM EDT